{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:43:25Z","timestamp":1762523005171,"version":"3.44.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00415-025-13188-9","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T14:24:30Z","timestamp":1749219870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective"],"prefix":"10.1007","volume":"272","author":[{"given":"Chiara","family":"Zanetta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Riva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"5","key":"13188_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/1744666X.2022.2064845","volume":"18","author":"C Zanetta","year":"2022","unstructured":"Zanetta C, Rocca MA, Filippi M (2022) Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients. Expert Rev Clin Immunol 18(5):495\u2013512","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"13188_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19(3):141\u2013154","journal-title":"Nat Rev Microbiol"},{"key":"13188_CR3","unstructured":"Douglas D (2016) Richman RJW FGH. Clinical Virology, 4th Edition"},{"issue":"20","key":"13188_CR4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"C Drosten","year":"2003","unstructured":"Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20):1967\u20131976","journal-title":"N Engl J Med"},{"issue":"14","key":"13188_CR5","doi-asserted-by":"publisher","first-page":"7790","DOI":"10.1128\/JVI.01244-13","volume":"87","author":"RJ de Groot","year":"2013","unstructured":"de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L et al (2013) Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group. J Virol 87(14):7790\u20137792","journal-title":"J Virol"},{"issue":"1","key":"13188_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","volume":"108","author":"J Wang","year":"2020","unstructured":"Wang J, Jiang M, Chen X, Montaner LJ (2020) Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol 108(1):17\u201341","journal-title":"J Leukoc Biol"},{"issue":"6","key":"13188_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00430-020-00693-z","volume":"209","author":"M Han","year":"2020","unstructured":"Han M, Xu M, Zhang Y, Liu Z, Li S, He T et al (2020) Assessing SARS-CoV-2 RNA levels and lymphocyte\/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. Med Microbiol Immunol 209(6):657\u2013668","journal-title":"Med Microbiol Immunol"},{"issue":"7821","key":"13188_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE et al (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature 584(7821):430\u2013436","journal-title":"Nature"},{"issue":"8","key":"13188_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s42399-020-00363-4","volume":"2","author":"A Sanyaolu","year":"2020","unstructured":"Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P et al (2020) Comorbidity and its Impact on patients with COVID-19. SN Compr Clin Med 2(8):1069\u20131076","journal-title":"SN Compr Clin Med"},{"issue":"1","key":"13188_CR10","doi-asserted-by":"publisher","first-page":"e1105","DOI":"10.1212\/NXI.0000000000001105","volume":"9","author":"MP Sormani","year":"2022","unstructured":"Sormani MP, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M et al (2022) COVID-19 severity in multiple sclerosis: putting data into context. Neurol Neuroimmunol Neuroinflamm 9(1):e1105","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"13188_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","volume":"78","author":"A Salter","year":"2021","unstructured":"Salter A, Fox RJ, Newsome SD, Halper J, Li DKB, Kanellis P et al (2021) Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol 78(6):699\u2013708","journal-title":"JAMA Neurol"},{"issue":"19","key":"13188_CR12","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","volume":"97","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C et al (2021) Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology 97(19):e1870\u2013e1885","journal-title":"Neurology"},{"issue":"2","key":"13188_CR13","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1212\/NXI.0000000000001141","volume":"9","author":"P Iaffaldano","year":"2022","unstructured":"Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M et al (2022) Risk of getting COVID-19 in people with multiple sclerosis: a case-control study. Neurol Neuroimmunol Neuroinflamm. 9(2):e1141","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"8","key":"13188_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11910-022-01211-9","volume":"22","author":"C Hollen","year":"2022","unstructured":"Hollen C, Bernard J (2022) Multiple sclerosis management during the COVID-19 pandemic. Curr Neurol Neurosci Rep 22(8):537\u2013543","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"13188_CR15","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-021-01410-w","volume":"27","author":"E Pritchard","year":"2021","unstructured":"Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD et al (2021) Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med 27(8):1370\u20131378","journal-title":"Nat Med"},{"issue":"15","key":"13188_CR16","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA et al (2021) BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 384(15):1412\u20131423","journal-title":"N Engl J Med"},{"issue":"2","key":"13188_CR17","first-page":"205521732110171","volume":"7","author":"XM Xiang","year":"2021","unstructured":"Xiang XM, Hollen C, Yang Q, Brumbach BH, Spain RI, Wooliscroft L (2021) COVID-19 vaccination willingness among people with multiple sclerosis. Mult Scler J Exp Transl Clin 7(2):20552173211017160","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"1","key":"13188_CR18","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/NXI.0000000000001104","volume":"9","author":"FBS Briggs","year":"2022","unstructured":"Briggs FBS, Mateen FJ, Schmidt H, Currie KM, Siefers HM, Crouthamel S et al (2022) COVID-19 vaccination reactogenicity in persons with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 9(1):e1104","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"6","key":"13188_CR19","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/13524585211003476","volume":"27","author":"A Achiron","year":"2021","unstructured":"Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S et al (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler 27(6):864\u2013870","journal-title":"Mult Scler"},{"issue":"12","key":"13188_CR20","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1001\/jamaneurol.2021.3599","volume":"78","author":"L Brill","year":"2021","unstructured":"Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E, Wolf DG et al (2021) Humoral and T-Cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol 78(12):1510\u20131514","journal-title":"JAMA Neurol"},{"issue":"11","key":"13188_CR21","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K et al (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27(11):1990\u20132001","journal-title":"Nat Med"},{"key":"13188_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100747","volume":"35","author":"RA Evans","year":"2023","unstructured":"Evans RA, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E et al (2023) Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur 35:100747","journal-title":"Lancet Reg Health Eur"},{"issue":"23","key":"13188_CR23","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A et al (2022) Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of COVID-19. N Engl J Med 386(23):2188\u20132200","journal-title":"N Engl J Med"},{"key":"13188_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578199","volume":"383","author":"S Gelibter","year":"2023","unstructured":"Gelibter S, Pirro F, Saraceno L, Susani E, Moioli MC, Puoti M et al (2023) Tixagevimab and cilgavimab use in multiple sclerosis and neuromyelitis optica spectrum disorder during anti-CD20 treatment: a single-center experience. J Neuroimmunol 383:578199","journal-title":"J Neuroimmunol"},{"key":"13188_CR25","unstructured":"Webber C BR, Thomas S, et al (2023) Trial in progress: a Phase I\/III, randomised, modified double-blind, placebo- and active-controlled pre-exposure prophylaxis study of the SARS-CoV-2\u2013neutralising antibody AZD3152 (SUPERNOVA) [Poster]. Presented at: ECCMID; Copenhagen, Denmark."},{"key":"13188_CR26","doi-asserted-by":"crossref","unstructured":"Francica JR CY, Diallo S, et al (2023) The SARS-CoV-2 monoclonal antibody AZD3152 potently neutralises historical and emerging variants and is being developed for the prevention and treatment of COVID-19 in high-risk individuals [poster]. Presented at: IDWeek 2023; Boston, MA, United States. Poster: 1355.","DOI":"10.1093\/ofid\/ofad500.1192"},{"key":"13188_CR27","unstructured":"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/supernova-trial-met-covid-19-prevention-endpoint.html."},{"key":"13188_CR28","unstructured":"https:\/\/data.who.int\/dashboards\/covid19\/cases aotD."},{"key":"13188_CR29","unstructured":"https:\/\/covid.cdc.gov\/covid-data-tracker\/#datatracker-home."},{"issue":"9","key":"13188_CR30","doi-asserted-by":"publisher","first-page":"e005427","DOI":"10.1136\/bmjgh-2021-005427","volume":"6","author":"M Michelen","year":"2021","unstructured":"Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C et al (2021) Characterising long COVID: a living systematic review. BMJ Glob Health 6(9):e005427","journal-title":"BMJ Glob Health"},{"issue":"1","key":"13188_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000385","volume":"2","author":"O Byambasuren","year":"2023","unstructured":"Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P (2023) Effect of COVID-19 vaccination on long COVID: systematic review. BMJ Med 2(1):e000385","journal-title":"BMJ Med"},{"key":"13188_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103905","volume":"63","author":"WL Conte","year":"2022","unstructured":"Conte WL, Golzarri-Arroyo L (2022) Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters. Mult Scler Relat Disord 63:103905","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"13188_CR33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/vaccines11020350","volume":"11","author":"D Jakimovski","year":"2023","unstructured":"Jakimovski D, Eckert SP, Mirmosayyeb O, Thapa S, Pennington P, Hojnacki D et al (2023) Tixagevimab and Cilgavimab (Evusheld) prophylaxis prevents breakthrough COVID-19 infections in immunosuppressed population: 6-month prospective study. Vaccines (Basel). 11(2):350","journal-title":"Vaccines (Basel)."},{"key":"13188_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00812-0","author":"D Focosi","year":"2025","unstructured":"Focosi D, Casadevall A (2025) Sipavibart: when a success changes into a failure. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(24)00812-0","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"13188_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.28997","volume":"5","author":"TS Anderson","year":"2022","unstructured":"Anderson TS, O\u2019Donoghue A, Mechanic O, Dechen T, Stevens J (2022) Administration of Anti-SARS-CoV-2 monoclonal antibodies after US food and drug administration deauthorization. JAMA Netw Open 5(8):e2228997","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13188-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13188-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13188-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:36:47Z","timestamp":1757183807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13188-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["13188"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13188-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C. Zanetta received compensation for speaking activities, and\/or consulting services, from Alexion, Amgen, Astrazeneca, Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, Sandoz, Sanofi. C. Gasperini received payment or honoraria for lectures, presentations, speakers bureaus, or educational events by Biogen, Merck, Roche, Novartis, Sanofi, Astra Zeneca, Sandoz. M.P. Amato has received research grants by the National MS Society, Canadian MS Society, Italian Health Ministry, Regione Toscana, Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva, Almirall, Roche, and honoraria as a speaker and member of advisory boards by Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva, Almirall, Roche, Celgene BMS, Sandoz. She is member of the Editorial Board of the Multiple Sclerosis Journal. D. Centonze acted as Advisory Board member of Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, SanofiGenzyme, and Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, and Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen Idec, Celgene, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva. P. Gallo has nothing to disclose. F. Patti has received honoraria for speaking activities by Alexion, Almirall, Bayer Schering, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA; he also served as advisory board member for the following companies: Bayer Schering, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA; he was funded by Pfizer and FISM for epidemiological studies; he received grants for congress participation from Alexion, Almirall, Bayer Shering, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA. A. Riva has received speaker\u2019s honoraria from the following companies: Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, ViiV, Gilead and MSD. M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology, received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA, participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda, scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme, he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable. The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"446"}}